Not an actual patient.
uncover the eligard® standard of care
divider line

WELCOME TO MORE

Proven efficacy1

ELIGARD delivers profound, reliable, and consistent T suppression to low levels

Customizable dosing1,2

Subcutaneous administration, with more injection site options and 4 dosing selections to meet individual patient needs

Extended control1,3

Unique in situ polymeric gel technology enables sustained efficacy through the dosing period

Unmatched access
& support

Responsible pricing, extensive services, and a comprehensive variety of resources ensure care continuity for both you and your patients

ELIGARD can be left at room temperature for up to 8 weeks (56 days) prior to mixing and administration, offering more flexibility for your practice1
T, testosterone.
References: 1. ELIGARD (leuprolide acetate). Prescribing Information. Tolmar, Inc. 2024. 2. Prettyman J, Engel L, Boldt-Houle DM, Atkinson S, Wilt W. Personalizing treatment in the delivery of care by nurses to patients with prostate cancer. Urologic Nursing. 2019;39(2):83-99. 3. Sartor O. Eligard®: a new form of treatment for prostate cancer. Eur Urol Open Sci. 2006;5(18):P905-P910.

You are now leaving
ELIGARDhcp.COM

Are you sure you want to leave? 

Skip to content